Merck & Co (MRK)
79.06
-0.23 (-0.29%)
NYSE · Last Trade: Jun 21st, 7:25 PM EDT
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.
Via Benzinga · June 20, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via Benzinga · June 20, 2025
Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move.
Via StockStory · June 19, 2025
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound.
Via Benzinga · June 18, 2025
Via Benzinga · June 18, 2025
MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.
Via Chartmill · June 18, 2025
"Too big to fail" is how we would describe the megacap stocks in this article today.
While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Via StockStory · June 18, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Via Stocktwits · June 17, 2025
The Dow Jones index could have fared better in May if not for these two stocks.
Via The Motley Fool · June 14, 2025
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.
Via Benzinga · June 13, 2025
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.
Via Stocktwits · June 13, 2025
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.
Via Benzinga · June 12, 2025
Via The Motley Fool · June 12, 2025
Via The Motley Fool · June 11, 2025
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.
Via Chartmill · June 10, 2025
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.
Via Benzinga · June 9, 2025
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.
Via Stocktwits · June 9, 2025
Via Benzinga · June 9, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via Chartmill · June 9, 2025
Each of the index's highest-yielding names has its own unique story right now.
Via The Motley Fool · June 7, 2025